- Telo Genomics (TSXV:TELO) has launched its physician experience program, SMART (Smoldering Multiple Myeloma Assessment of Risk for Transformation) in the United States
- SMART is an observational study geared towards cancer-treating physicians
- Physicians will have access to novel molecular information in choosing management strategies for patients diagnosed with smoldering multiple myeloma
- Shares of Telo Genomics are down 6.82 per cent to C$0.205 as of 10:02 am ET
Telo Genomics (TSXV:TELO) has launched its physician experience program SMART (Smoldering Multiple Myeloma Assessment of Risk for Transformation) in the United States.
In a news release, the company stated that SMART is an observational study geared toward physicians who treat cancer.
Through the platform, physicians will have access to novel molecular information in choosing management strategies in patients who have smoldering multiple myeloma, which is an early sign in developing multiple myeloma, a blood cancer. Physicians will also be able to gain experience ordering and utilizing the TeloViewSMM assay.
TeloViewSMM is a non-invasive liquid biopsy, using three-dimensional telomere analysis that uses the TeloView platform to quantify genomic instability and transformation risk.
“I’m encouraged that new biomarkers and novel approaches are being pursued in this patient population,” Richard A. Bender, chairman of Telo Genomic’s clinical advisory board, said in a statement. ” Having access to the TeloViewSMM assay promises to improve the management of my patients with Smoldering Multiple Myeloma.”
The SMART study was initiated by the company just this month to assess clinical and laboratory dynamics around the use of TeloViewSMM.
Telo Genomics is focused on developing its telomere platform with powerful applications and predictive/prognostic solutions, including liquid biopsies and related technologies in oncology and neurological diseases.
Shares of Telo Genomics are down 6.82 per cent to C$0.205 as of 10:02 am ET.
Join the discussion: Find out what everybody’s saying about this stock on the Telo Genomics Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.